Compare Act I : The AI Prophecy (ACT) vs Bio Protocol (BIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Act I : The AI Prophecy vs Bio Protocol — how do they compare? Act I : The AI Prophecy trades at Rp169.47 (market cap Rp159,94M, Rp438,74M 24h volume), while Bio Protocol trades at Rp441.25 (market cap Rp1,01T, Rp168,09M 24h volume). The key difference: Bio Protocol is far larger — about 6314.9× Act I : The AI Prophecy's market cap, and Bio Protocol's supply is capped (2,3B / 3,3B BIO (69%)) while Act I : The AI Prophecy's keeps growing. Which is the better fit depends on your goals — on Pluang, investors hold Act I : The AI Prophecy for 38 Days and Bio Protocol for 18 Days on average.
| ACT | BIO | |
|---|---|---|
Market Cap | Rp159,94M | Rp1,01T |
Volume (24h) | Rp438,74M | Rp168,09M |
Circulating Supply | 948,2M ACT | 2,3B / 3,3B BIO (69%) |
Typical Hold Time | 38 Days | 18 Days |
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Act I : The AI Prophecy
Act I: The AI Prophecy Project (commonly known as Act I) is an open-source, decentralized platform that fosters unique interactions between AI systems. It aims to create an ecosystem where various AI, powered by a specialized token called ACT, can collaborate with each other and human users. Act I seeks to redefine traditional AI chatbots by emphasizing creativity over the standard “helpful, harmless, and honest” principles. By enabling collaboration between different types of AI, such as text and image generators, Act I strives to advance the development of more sophisticated AI technologies.
Read more on ACT →About Bio Protocol
BIO Protocol enables global communities of scientists, patients, and investors to collectively fund, develop, and co-own new drugs and therapeutics through its network of Biotech Decentralized Autonomous Organizations (BioDAOs). The protocol's innovative approach addresses critical gaps in traditional scientific funding, particularly in areas such as rare diseases, longevity research, and emerging health challenges.
Read more on BIO →
